Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 17, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing details increases in notional interest in GSK Ordinary Shares and American Depositary Shares (ADSs) resulting from the re-investment of dividends paid on July 13, 2017, under the Company's 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions. Key transaction metrics include:
- Transaction Date: July 14, 2017
- Instrument Types: Ordinary Shares (ISIN: GB0009252882) and American Depositary Shares (ISIN: US37733W1053)
- Transaction Price (Ordinary Shares): £16.18 per share
- Transaction Price (ADSs): $42.50 per ADS
- Total Volume Reported: Aggregated volumes across 12 executives range from approximately 449 to 2,007 shares/ADSs per individual.
Material Changes
The filing does not report material changes to the company's business operations, financial condition, or market position. The only changes reported are the incremental increases in shareholdings for specific executives due to automatic dividend re-investment plans. No open market purchases or sales were disclosed.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is a statutory disclosure of routine compensation-related share transactions.
Important Facts for Investors
- Executive Participation: Twelve senior executives, including CEO Emma Walmsley and CFO Simon Dingemans, participated in the dividend re-investment plan.
- Transaction Nature: All reported transactions were non-discretionary increases in notional interest via dividend re-investment, not open market trades.
- Share Price Context: The transactions occurred at a fixed price of £16.18 for Ordinary Shares and $42.50 for ADSs on July 14, 2017.
- No Financial Data: Investors should not use this filing to assess GSK's quarterly or annual financial performance; it contains no revenue or earnings data.